Vertex Pharmaceuticals Inc.
Company Snapshot
Company Overview
Vertex Pharmaceuticals is a global biotechnology company dedicated to advancing scientific innovation to develop transformative medicines for individuals with serious diseases, particularly in specialty markets. Their portfolio includes four approved medications addressing the root cause of cystic fibrosis (CF), a life-threatening genetic disorder, and a therapy approved for severe sickle cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT), both of which are life-shortening inherited blood disorders. Their pipeline features clinical-stage programs targeting CF, SCD, beta thalassemia, acute and neuropathic pain, APOL1-mediated kidney disease, type 1 diabetes, myotonic dystrophy type 1, and alpha-1 antitrypsin deficiency. Vertex is also researching a novel treatment approach for Duchenne muscular dystrophy based on CRISPR/cas9 gene-editing technology. It is also reported that for CASGEVY.
Financial Highlights (FY 2024)
This information is available for BCC Research members only.
Company's Business Segments
- TRIKAFTA/KAFTRIO : Elexacaftor/Tezacaftor/Ivacaftor, Ivacaftor
- KALYDECO : Ivacaftor
- ORKAMBI : Lumacaftor/Ivacaftor
- SYMDEKO/SYMKEVI : Tezacaftor/Ivacaftor, Ivacaftor
Applications/End User Industries
- Healthcare
- Pharmaceuticals
